← Back to Search

Anti-obesity agent

Counselling for Obesity

Phase 4
Waitlist Available
Led By Trina M Aguirre
Research Sponsored by University of Nebraska
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Overweight/Obese Adult patients (age 19 years -65)
eligible based on WALI screening tool
Timeline
Screening 3 weeks
Treatment Varies
Follow Up difference between baseline and 6 months
Awards & highlights

Study Summary

This trial is testing whether pharmacological therapy, individual motivational interviewing, or a combination of the two is more effective than usual care in improving outcome measures for obese people who test positive or negative for food addiction.

Eligible Conditions
  • Obesity

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~difference between baseline and 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and difference between baseline and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
body fat
weight

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: CounsellingExperimental Treatment2 Interventions
These participants will receive usual care and counseling in the form of motivational interviewing weekly with goal setting for the first 5 weeks and monthly intervention for the final 5 months.
Group II: Contrave and counselingExperimental Treatment4 Interventions
These participants will receive usual care of diet and physical activity recommendations and Contrave prescription and counseling (motivational interviewing interventions weekly for the first 5 weeks and then monthly for 5 months.
Group III: ContraveExperimental Treatment2 Interventions
These participants will receive usual care and prescription of Contrave for weight loss. They will be seen weekly for the first 5 weeks and monthly for the final 5 months.
Group IV: Intervention ControlActive Control1 Intervention
All participants will receive diet/physical intervention. One arm will receive diet/physical activity intervention alone as a Intervention/usual care condition.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Intervention Control
2017
Completed Phase 4
~90
Naltrexone
FDA approved
Naltrexone
FDA approved
Counselling
2010
Completed Phase 4
~21150

Find a Location

Who is running the clinical trial?

University of NebraskaLead Sponsor
535 Previous Clinical Trials
1,143,823 Total Patients Enrolled
10 Trials studying Obesity
3,366 Patients Enrolled for Obesity
Trina M AguirrePrincipal InvestigatorUniversity of Nebraska

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~11 spots leftby Mar 2025